Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks

Aims/Introduction:  Since glycated albumin (GA) reflects shorter‐term (about 2 weeks) control of plasma glucose levels compared with HbA1c, GA is thought to be a useful glycemic control indicator for the early period following commencement of the treatment of diabetes. In this study, we attempted to estimate HbA1c using the change in GA level before and after the first 2 weeks (ΔGA2w) of administration of sitagliptin, a dipeptidyl peptidase‐4 (DPP‐4) inhibitor.

• Publication year

  2011

• Venue

  Journal of Diabetes Investigation

• Publication date

  2011-10-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.2040-1124.2011.00167.xPMID 24843562PMCID 4020736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia.

  2011cited by this paper
• Prediction of near‐future glycated hemoglobin levels using glycated albumin levels before and after treatment for diabetes

  2011cited by this paper
• Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM).

  2010cited by this paper
• Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

  2010cited by this paper
• Clinical impact of glycated albumin as another glycemic control marker.

  2010cited by this paper
• Lucica GA-L glycated albumin assay kit: a new diagnostic test for diabetes mellitus.

  2010cited by this paper
• Predicting steady‐state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus *

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes.

  2008cited by this paper
• Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control.

  2007cited by this paper
• Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection.

  2007cited by this paper
• Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin

  2007cited by this paper
• Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

  2006cited by this paper
• Silent hemoglobin variants and determination of HbA(1c) with the high-resolution program of the HPLC HA-8160 hemoglobin analyzer.

  2005cited by this paper
• An enzymatic method for the measurement of glycated albumin in biological samples.

  2002cited by this paper
• The Diabetes Control and Complications Trial

  1998cited by this paper
• Kinetics of HbA1c, Glycated Albumin, and Fructosamine and Analysis of Their Weight Functions Against Preceding Plasma Glucose Level

  1995cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Nonenzymatic glycation: a central mechanism in diabetic microvasculopathy?

  1988cited by this paper
• Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites.

  1986cited by this paper
• The glycosylation of hemoglobin: relevance to diabetes mellitus.

  1978cited by this paper
• Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus.

  1976cited by this paper

• Psoriasis in Al - Anbar Government clinical and epidemiological study

  2021cites this paper
• Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality.

  2020cites this paper
• Glycated albumin is a better indicator for glucose levels than glycated hemoglobin in patients with diabetes mellitus on insulin therapy

  2020cites this paper
• Usefulness of glycated albumin in decisions regarding the discontinuation of a diabetes drug and factors associated with poor glycemic control following discontinuation in patients with type 2 diabetes mellitus

  2017influential citation
• Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1.

  2016cites this paper
• A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment.

  2015cites this paper
• Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin

  2015cites this paper
• 1,5-Anhydroglucitol and glycated albumin in glycemia.

  2014cites this paper
• Alogliptin benzoate for the treatment of type 2 diabetes

  2014cites this paper
• Glycated albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes.

  2014cites this paper
• Glycated albumin; clinical usefulness.

  2014cites this paper
• Prediction of near-future HbA1c levels using glycated albumin levels before and after glimepiride administration for 2 weeks is useful to determine the effectiveness of the treatment

  2012cites this paper